Northland Biotech Announces Plan to Invest Up to RMB 30 Million in Ophthalmic Solution Production Line and Supporting Facilities

Northland announced on May 10 that its subsidiary, Beijing Huonland Pharmaceutical Co., Ltd., plans to invest no more than 30 million yuan during 2023-2024 to purchase production lines and supporting facilities for eye drops, based on the needs of production, operation, and future development. The specific details will depend on project requirements and actual implementation.